Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Association of UDP-glucuronosyltransferase 1A1 (UGT1A1) genetic polymorphisms *6 and *28 with reduced clearance of SN-38 and severe neutropenia in irinotecan therapy was demonstrated in Japanese cancer patients. * The detailed gene structure of CES1 has been characterized. * Possible functional SNPs in the promoter region have been reported. WHAT THIS STUDY ADDS * Association of functional CES1 gene number with AUC ratio [(SN-38 + SN-38G)/irinotecan], an in vivo index of CES activity, was observed in patients with irinotecan monotherapy. * No significant effects of major CES1 SNPs on irinotecan PK were detected. AIMS Human carboxylesterase 1 (CES1) hydrolyzes irinotecan to produce an active metabolite SN-38 in the liver. The human CES1 gene family consists of two functional genes, CES1A1 (1A1) and CES1A2 (1A2), which are located tail-to-tail on chromosome 16q13-q22.1 (CES1A2-1A1). The pseudogene CES1A3 (1A3) and a chimeric CES1A1 variant (var1A1) are also found as polymorphic isoforms of 1A2 and 1A1, respectively. In this study, roles of CES1 genotypes and major SNPs in irinotecan pharmacokinetics were investigated in Japanese cancer patients. METHODS CES1A diplotypes [combinations of haplotypes A (1A3-1A1), B (1A2-1A1), C (1A3-var1A1) and D (1A2-var1A1)] and the major SNPs (-75T>G and -30G>A in 1A1, and -816A>C in 1A2 and 1A3) were determined in 177 Japanese cancer patients. Associations of CES1 genotypes, number of functional CES1 genes (1A1, 1A2 and var1A1) and major SNPs, with the AUC ratio of (SN-38 + SN-38G)/irinotecan, a parameter of in vivo CES activity, were analyzed for 58 patients treated with irinotecan monotherapy. RESULTS The median AUC ratio of patients having three or four functional CES1 genes (diplotypes A/B, A/D or B/C, C/D, B/B and B/D; n= 35) was 1.24-fold of that in patients with two functional CES1 genes (diplotypes A/A, A/C and C/C; n= 23) [median (25th-75th percentiles): 0.31 (0.25-0.38) vs. 0.25 (0.20-0.32), P= 0.0134]. No significant effects of var1A1 and the major SNPs examined were observed. CONCLUSION This study suggests a gene-dose effect of functional CES1A genes on SN-38 formation in irinotecan-treated Japanese cancer patients.

[1]  Teruhiko Yoshida,et al.  Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients , 2010, Cancer Chemotherapy and Pharmacology.

[2]  Soma Das,et al.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. McLeod,et al.  Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes , 2008, Pharmacogenetics and genomics.

[4]  Teruhiko Yoshida,et al.  Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients , 2008, Cancer Chemotherapy and Pharmacology.

[5]  Tomomi Kimura,et al.  Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. , 2008, Biochemical and biophysical research communications.

[6]  S. Hirohashi,et al.  Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. , 2008, Cancer letters.

[7]  Masakiyo Hosokawa,et al.  Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs , 2008, Molecules.

[8]  Teruhiko Yoshida,et al.  Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population , 2007, Drug Metabolism and Disposition.

[9]  Teruhiko Yoshida,et al.  Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.

[10]  K. Tanimoto,et al.  Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro , 2007, Pharmacogenetics & Genomics.

[11]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Teruhiko Yoshida,et al.  FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2) , 2005, Drug Metabolism and Disposition.

[13]  Tomomi Kimura,et al.  A Single Nucleotide Polymorphism in the Carboxylesterase Gene Is Associated with the Responsiveness to Imidapril Medication and the Promoter Activity , 2005, Hypertension Research.

[14]  J. Robert,et al.  Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38 , 2004, Clinical pharmacology and therapeutics.

[15]  P. Kwok,et al.  Pharmacogenomic assessment of carboxylesterases 1 and 2. , 2004, Genomics.

[16]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Teruhiko Yoshida,et al.  Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan , 2003 .

[18]  T. Morisaki,et al.  Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm , 2002 .

[19]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[20]  M. Dolan,et al.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.

[21]  Ji-Youn Han,et al.  Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. , 2009, Lung cancer.

[22]  Kaoru Kobayashi,et al.  Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. , 2008, Drug metabolism and pharmacokinetics.

[23]  Teruhiko Yoshida,et al.  Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. , 2003, Pharmacogenetics.

[24]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.